Shaanxi Meibang Pharmaceutical Group Co., Ltd.SSE: 605033

Evaluation Report on the "Corporate Value and Return Enhancement" Action Plan for 2026

· Issued by Shaanxi Meibang Pharmaceutical Group Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 3 pages · Chinese

Summary by 6ix AI

The report highlights the company's focus on improving operational quality and enhancing core competitiveness through innovation and effective management strategies. It also emphasizes the company's commitment to stable profit distribution and investor returns, alongside efforts to improve information disclosure and corporate governance.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Release

Evaluation Report on the "Corporate Value and Return Enhancement" Action Plan for 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Shaanxi Meibang Pharmaceutical Group Co., Ltd. on 6ix

Earlier from Shaanxi Meibang Pharmaceutical

Later from Shaanxi Meibang Pharmaceutical

All Shaanxi Meibang Pharmaceutical news releases